HOME > ARCHIVE
ARCHIVE
- AstraZeneca to Recommend 5 mg Starting Dose of Crestor to Asians: EU Label
May 16, 2005
- Mediceo HD to Merge with Paltac
May 9, 2005
- DPC Hospitals Conducting More Advanced Medical Procedures
May 9, 2005
- Huntingdon Life Sciences to Strengthen Business with Japanese Clients
May 9, 2005
- Just 10.9% of Hospitals Have Switched to Generics Since Introduction of DPC
May 9, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 9, 2005
- Chuikyo Starts Studies on Med Services Provided Beyond Designated Number of Times
May 9, 2005
- DPC Increased Use of Generics in 55.6% of Hospital: Prof. Kawabuchi
May 9, 2005
- NHI Pricing Rule Needs Radical Revisions: Chuikyo
May 9, 2005
- 41.2% of Suspected COPD Patients Do Not Intend to Consult a Physician
May 9, 2005
- CPhI Japan/ICSE Japan 2005
May 9, 2005
- Draft GL on Management of Pancreatic Cancer Published: JSGE
May 9, 2005
- BUSINESS NEWS IN BRIEF
May 9, 2005
- R&D NEWS IN BRIEF
May 9, 2005
- JPMA to Introduce "Good Communication 2005" Campaign
May 9, 2005
- Chugai, 2 Partners Establish Drug Discovery Research Institute
May 9, 2005
- BULLETIN
May 9, 2005
- Maximize Product Value as Competition Heats Up: Mr Suganuma
May 9, 2005
- KSK Will Not Join the Kyoso Mirai Group: Mr Fukada
May 9, 2005
- Mochida Aiming for Sales of \76 Bil. in FY2007
May 9, 2005
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
